Simon, Dagmar; Simon, Hans-Uwe (2012). New drug targets in atopic dermatitis. Chemical immunology and allergy, 96, pp. 126-131. Basel: Karger
Full text not available from this repository. (Request a copy)Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by eczematous skin lesions, pruritus and typical histopathological features. T cells are thought to play a key role, but B cells might also participate in the pathogenesis of AD. In two investigator-initiated pilot studies, we studied the effects of B cell depletion by monoclonal anti-CD20 antibody therapy or a reduction of activated T cells by LFA3-IgG fusion protein on moderate-to-severe AD. All patients treated with either rituximab or alefacept showed an improvement of their skin symptoms with a sustained effect after treatment. In both studies, histological alterations, such as spongiosis, acanthosis and dermal infiltrate, including T and B cell numbers, dramatically improved and the expression of IL-5 and IL-13 was reduced after therapy. Upon rituximab therapy, allergen-specific IgE levels were not altered and total serum IgE levels only slightly decreased. According to recent studies, neutralizing B and T cells products such as IgE or IL-5 might be effective in subgroups of patients with AD.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology 04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology |
UniBE Contributor: |
Simon, Dagmar, Simon, Hans-Uwe |
ISSN: |
1660-2242 |
Publisher: |
Karger |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:35 |
Last Modified: |
05 Dec 2022 14:11 |
PubMed ID: |
22433382 |
Web of Science ID: |
000304075400019 |
URI: |
https://boris.unibe.ch/id/eprint/14110 (FactScience: 220920) |
Actions (login required)
 |
Edit item |